OncoHealth

Forty years ago, researchers discovered one of cancer's most elusive drivers. Today, oncology is beginning to learn what happens when that driver can finally be shut off. Author: Corey Wise, Sr. Clinical Pharmacist After nearly four decades of failed atte

By Richa Madurkar, PharmD, BCOP, Senior Lead Clinical Pharmacist at OncoHealth Key Takeaways Novel oncology drugs and new treatment pathways presented at ASCO are positioned to change the treatment landscape across several different types of cancer Payors

Author: Melissa Pozotrigo, PharmD, BCOP Minimal residual disease (MRD) testing has become one of the most important advances in cancer care over the past twenty years. It can find very small amounts of remaining disease that standard methods such as blood

The post Webinar: Translating ASCO 2026: What Matters Most for Managed Care appeared first on OncoHealth.

Cancer care is often measured in clinical milestones such as diagnosis, treatment, and remission. But for many individuals, the experience extends beyond physical care. Mental health concerns are common, complex, and closely connected to overall outcomes.

Authors: Adam Leikensohn, MD & Richa Madurkar, PharmD, BCOP The treatment landscape for bladder cancer is rapidly evolving. Additional therapeutic options have been recently approved or are in the pipeline for patients in both non-muscle invasive and musc

Genetic and molecular testing is transforming oncology care, but it is also introducing a new layer of complexity, cost, and clinical risk for health plans. In 2024, Medicare Part B spending on human genetic tests surpassed $2 billion for the first time,

The post What's Next in Oncology: 6 Pivotal Drug Approvals for 2026 appeared first on OncoHealth.

For years, health plan oncology strategy has focused primarily on cancer treatment using tools like prior authorization, clinical pathways, drug preference mandates, and site-of-care optimization. While these remain critical, they are no longer sufficient

Author: Richa Madurkar, PharmD, BCOP, Senior Clinical Oncology Pharmacist, OncoHealth Until recently, standard first-line treatment options for CLL included indefinite therapy with a covalent BTK inhibitor (cBTKi) such as ibrutinib, acalabrutinib, or zanu